Good morning and welcome to Markets Desk, your midday read on what's moving the tape.
Arthur J. Gallagher delivered a strong third quarter, with total revenues before reimbursements climbing to three billion nine hundred thirty million dollars, up sharply from three billion three hundred twenty-five million a year ago. Net earnings came in at four hundred six million, signaling continued momentum in the insurance brokerage space as the firm benefits from both organic growth and acquisition activity.
Turning to industrials, Ingersoll Rand posted reported revenues of two billion sixty-five million for the third quarter, up six percent, or four percent on an organic basis. The more striking number was orders, which surged twenty-one percent to two billion three hundred forty-five million, suggesting the demand pipeline remains robust even as management updated full-year guidance, a move the market will parse closely for tone.
And in the oncology space, Daiichi Sankyo reported a sixteen percent rise in first-half profit, lifted by its cancer franchise, particularly Enhertu and Datroway, two antibody-drug conjugates that have become central to its growth story. Favorable currency movements provided an additional tailwind, and the company backed its full fiscal twenty-six outlook, offering investors a measure of confidence heading into the second half.
That's the tape. Markets Desk, signing off the floor.
